CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 742 enrolled
Drug / intervention
Liberal RBC Transfusion Strategy +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03309579
NCT03309579N/ACompleted
CompareCT.gov

Aneurysmal Subarachnoid Hemorrhage - Red Blood Cell Transfusion and Outcome (SAHaRA): A Randomized Controlled Trial

Ottawa Hospital Research Institute·interventional·Posted Oct 13, 2017·Updated Nov 6, 2024

In Brief

A clinical study evaluating Liberal RBC Transfusion Strategy and Restrictive RBC Transfusion Strategy for Subarachnoid Hemorrhage, Aneurysmal. Completed, enrolled 742 participants across 23 sites in 3 countries.

Detailed Summary

The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strategy in patients with aSAH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubarachnoid Hemorrhage, Aneurysmal
CountriesAustralia, Canada, United States
CollaboratorsCanadian Institutes of Health Research (CIHR)

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 13, 2017
Enrollment StartFeb 12, 2018
Primary CompletionJul 10, 2024
Study CompletionAug 22, 2024
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 8.7 years ago

Interventions

Liberal RBC Transfusion Strategyother

RBC transfusion is triggered by a Hemoglobin value of ≤100g/L

Restrictive RBC Transfusion Strategyother

Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L